Clinical indications for indometacin include:Joint diseases

rheumatoid arthritis
ankylosing spondylitis
osteoarthritis
gouty arthritis
acute painful shoulder bursitis or tendinitisHeadaches

Trigeminal autonomic cephalgias
Paroxysmal hemicranias
Chronic paroxysmal hemicrania
Episodic paroxysmal hemicrania
Hemicrania continua
Valsalva-induced headaches
Primary cough headache
Primary exertional headache
Primary headache associated with sexual activity (preorgasmic and orgasmic)
Primary stabbing headache (jabs and jolts syndrome)
Hypnic headacheOthers

Patent ductus arteriosus

Contraindications
Concurrent peptic ulcer, or history of ulcer disease
Allergy to indometacin, aspirin, or other NSAIDs
Roux-en-Y gastric bypass and gastric sleeve patients
Patients with nasal polyps reacting with an angioedema to other NSAIDs
Children under 2 years of age (with the exception of neonates with patent ductus arteriosus)
Severe pre-existing renal and liver damage
Caution: pre-existing bone marrow damage (frequent blood cell counts are indicated)
Caution: bleeding tendencies of unknown origin (indometacin inhibits platelet aggregation)
Caution: Parkinsons disease, epilepsy, psychotic disorders (indometacin may worsen these conditions)
Concurrent with potassium sparing diuretics
Patients who have a patent ductus arteriosus dependent heart defect (such as transposition of the great vessels)
Significant hypertension (high blood pressure)
Concomitant administration of lithium salts (such as lithium carbonate)

Adverse effects
In general, adverse effects seen with indometacin are similar to all other NSAIDs. For instance,  indometacin inhibits both cyclooxygenase-1 and cyclooxygenase-2, which then inhibits the production of prostaglandins in the stomach and intestines responsible for maintaining the mucous lining of the gastrointestinal tract. Indometacin, therefore, like other non-selective COX inhibitors, can cause peptic ulcers. These ulcers can result in serious bleeding or perforation, requiring hospitalization of the patient. To reduce the possibility of peptic ulcers, indometacin should be prescribed at the lowest dosage needed to achieve a therapeutic effect, usually between 50 and 200 mg/day. It should always be taken with food.
This part of 1q21.1 is involved in the development of the brain. It is assumed to be a dosage-sensitive gene. When this gene is not available in the 1q21.1 area, it leads to microcephaly. HYDIN2 is a recent duplication (found only in humans) of the HYDIN gene found on 16q22.2. Research on the genes CHD1L and PRKAB2 within lymphoblast cells  lead to the conclusion that anomalies appear with the 1q21.1-deletion syndrome:

CHD1L is an enzyme which is involved in untangling the chromatides and the DNA repair system. With 1q21.1 deletion syndrome a disturbance occurs, which leads to increased DNA breaks. The role of CHD1L is similar to that of helicase with the Werner syndrome
PRKAB2 is involved in maintaining the energy level of cells. With 1q21.1-deletion syndrome this function was attenuated.GJA5 has been identified as the gene that is responsible for the phenotypes observed with congenital heart diseases on the 1q21.1 location. In case of a duplication of GJA5 tetralogy of Fallot is more common. In case of a deletion other congenital heart diseases than tetralogy of Fallot are more common. References
Further reading
External links
DECIPHER database entry for 1q21.1 deletion syndrome
1q21.1 deletion, GeneReviews NCBI Bookshelf
Orpha.net